NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free CASI Stock Alerts $3.03 -0.15 (-4.72%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.93▼$3.2550-Day Range$3.03▼$7.8552-Week Range$1.60▼$8.48Volume65,982 shsAverage Volume226,943 shsMarket Capitalization$40.54 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CASI Pharmaceuticals alerts: Email Address CASI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside296.0% Upside$12.00 Price TargetShort InterestHealthy0.73% of Float Sold ShortDividend StrengthN/ASustainability-1.50Upright™ Environmental ScoreNews Sentiment0.78Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.66 out of 5 starsMedical Sector76th out of 947 stocksBiological Products, Except Diagnostic Industry10th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, CASI Pharmaceuticals has a forecasted upside of 296.0% from its current price of $3.03.Amount of Analyst CoverageCASI Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.73% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 21.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CASI Pharmaceuticals is -1.50. Previous Next 3.8 News and Social Media Coverage News SentimentCASI Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CASI Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for CASI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.62% of the stock of CASI Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About CASI Pharmaceuticals Stock (NASDAQ:CASI)CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Read More CASI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CASI Stock News HeadlinesMarch 18, 2024 | finanznachrichten.deAptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe ConferenceMarch 16, 2024 | finance.yahoo.comCASI Apr 2024 2.500 callMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 12, 2024 | americanbankingnews.comStockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI)March 11, 2024 | markets.businessinsider.comPsyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic DivisionMarch 8, 2024 | msn.comAptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare moversMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 10.000 callMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 7.500 putMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 5, 2024 | msn.comCASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese PatientsMarch 5, 2024 | msn.comCASI stock rises on positive interim data from early stage trial for its NHL treatment in ChinaMarch 5, 2024 | marketwatch.comCASI Pharma Shares Soar After Positive Preliminary Trial Data for Cancer ImmunotherapyMarch 5, 2024 | prnewswire.comCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaFebruary 20, 2024 | msn.comCASI begins dosing lymphoma patients with pralatrexate in ChinaFebruary 18, 2024 | msn.comCASI Pharmaceuticals Reveals Business and Financial Updates Quarter 2024February 16, 2024 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINAFebruary 16, 2024 | prnewswire.comCASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINAFebruary 13, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: CymaBay Therapeutics (CBAY), G1 Therapeutics (GTHX) and Gritstone Oncology (GRTS)January 31, 2024 | es-us.finanzas.yahoo.comEnhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific OfficerJanuary 3, 2024 | finance.yahoo.comSwitch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology OfficerDecember 28, 2023 | benzinga.comCASI Pharmaceuticals Stock (NASDAQ:CASI) Dividends: History, Yield and DatesDecember 18, 2023 | finance.yahoo.comCASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Price Is Right But Growth Is Lacking After Shares Rocket 33%December 16, 2023 | morningstar.comCASI Pharmaceuticals Inc CASINovember 15, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To KnowNovember 14, 2023 | markets.businessinsider.comCASI Pharmaceuticals Posts Narrower Loss In Q3November 14, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$0.35, revenue of $8.84MNovember 14, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESSee More Headlines Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today3/18/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CASI CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees224Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+296.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,010,000.00 Net Margins-95.24% Pretax Margin-87.15% Return on Equity-110.90% Return on Assets-47.81% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.17 Sales & Book Value Annual Sales$43.11 million Price / Sales0.94 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book0.92Miscellaneous Outstanding Shares13,380,000Free Float10,537,000Market Cap$40.54 million OptionableOptionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Wei-Wu He Ph.D. (Age 59)Chairman & CEO Comp: $565.36kDr. Wei Zhang Ph.D. (Age 64)President Comp: $1.13MDr. Alexander A. Zukiwski M.D. (Age 67)Executive VP & Chief Medical Officer Comp: $514.79kMs. Kun Qian (Age 42)VP & Global Controller Ms. Chunhua Wang (Age 52)Chief Operating Officer Ms. Wei Gao (Age 43)General Counsel Dr. James E. Goldschmidt Ph.D.Chief Business Development OfficerMr. Hai HuangGlobal Chief Commercial OfficerMs. Amanda CuiVP & Global ControllerMore ExecutivesKey CompetitorsJATT AcquisitionNYSE:JATTAVROBIONASDAQ:AVROQuince TherapeuticsNASDAQ:QNCXCortexymeNASDAQ:CRTXCurisNASDAQ:CRISView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 1,300 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions CASI Stock Analysis - Frequently Asked Questions Should I buy or sell CASI Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks. What is CASI Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 12 month price targets for CASI Pharmaceuticals' stock. Their CASI share price targets range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 296.0% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts. How have CASI shares performed in 2024? CASI Pharmaceuticals' stock was trading at $7.16 on January 1st, 2024. Since then, CASI shares have decreased by 57.7% and is now trading at $3.03. View the best growth stocks for 2024 here. Are investors shorting CASI Pharmaceuticals? CASI Pharmaceuticals saw a drop in short interest during the month of February. As of February 29th, there was short interest totaling 41,800 shares, a drop of 21.3% from the February 14th total of 53,100 shares. Based on an average trading volume of 200,500 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.7% of the shares of the stock are sold short. View CASI Pharmaceuticals' Short Interest. When is CASI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our CASI earnings forecast. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.27. The biotechnology company earned $9.82 million during the quarter, compared to the consensus estimate of $10.09 million. CASI Pharmaceuticals had a negative net margin of 95.24% and a negative trailing twelve-month return on equity of 110.90%. When did CASI Pharmaceuticals' stock split? Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM). Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang and Wei-Wu He. View institutional ownership trends. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CASI) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.